Země: Irsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
ACETYLSALICYLIC ACID
Uniphar plc
B01AC06
ACETYLSALICYLIC ACID
75 Milligram
Tablets Gastro-Resistant
Product subject to prescription which may be renewed (B)
Platelet aggregation inhibitors excl. Heparin
Authorised
2011-10-14
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nuasa 75 mg gastro-resistant tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablet contains 75 mg aspirin (acetylsalicylic acid). Excipients: Each tablet contains 45 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant tablet White gastro-resistant coated tablets, round and biconvex, without break-score. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - For decreasing the risk of myocardial infarction in patients with stable and unstable angina pectoris. - Secondary prophylaxis after myocardial infarction. - Prophylaxis of thrombosis after vascular surgery e.g. coronary bypass surgery. - For the secondary prevention of transient ischaemic attacks (TIA) and stroke provided that intracerebral haemorrhages have been ruled out. Nuasa 75 mg gastro-resistant tablets are not recommended for the use in emergency situations but are restricted to chronic treatment only. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Decreasing the risk of myocardial infarction in patients with stable and unstable angina pectoris_: 75 to 150 mg per day _Secondary prophylaxis after myocardial infarction_ 75 to 150 mg per day _Prophylaxis of thrombosis after vascular surgery e.g. coronary bypass surgery_ 100 to 300 mg per day _Secondary prevention of transient ischaemic attacks (TIA) and stroke_ 75 to 150 mg per day ASA is suitable for long-term treatment with the lowest effective dose. _Elderly patients_ ASA should be used with caution in elderly patients as they are at higher risk for adverse events. _Paediatric population_ ASA should not be given to children below 16 years of age because of safety concerns (see section 4.4). IRISH MEDICINES BOARD _______________ Přečtěte si celý dokument